U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O2
Molecular Weight 314.4617
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DRONABINOL

SMILES

[H][C@@]12CCC(C)=C[C@@]1([H])C3=C(O)C=C(CCCCC)C=C3OC2(C)C

InChI

InChIKey=CYQFCXCEBYINGO-IAGOWNOFSA-N
InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H30O2
Molecular Weight 314.4617
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf

Dronabinol also known as (−)-trans-delta9-tetrahydrocannabinol is an active ingredient of cannabis. The drug was approved by FDA for the treatment of anorexia in patients with AIDS and chemotherapy-induced nausea and vomiting. Dronabinol exerts its action by activating CB1 and CB2 recepors which makes it a CNS active medicine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P34972
Gene ID: 1269.0
Gene Symbol: CNR2
Target Organism: Homo sapiens (Human)
3.13 nM [Ki]
Target ID: P21554|||Q5UB37
Gene ID: 1268.0
Gene Symbol: CNR1
Target Organism: Homo sapiens (Human)
5.05 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

1985
Secondary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

1985
Secondary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

1985
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.88 ng/mL
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1.32 ng/mL
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.96 ng/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15.2 ng × h/mL
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.88 ng × h/mL
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6.16 ng × h/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3%
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3%
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Other AEs: Palpitations, Tachycardia...
Other AEs:
Palpitations (2.5%)
Tachycardia (2.5%)
Photophobia (2.5%)
Vision blurred (2.5%)
Eye irritation (2.5%)
Dry mouth (40%)
Fatigue (30%)
Feeling of relaxation (5%)
Hunger (10%)
Feeling hot (5%)
Thirst (5%)
Chills (2.5%)
Upper respiratory tract infection (2.5%)
Hordeolum (2.5%)
Increased appetite (7.5%)
Polydipsia (2.5%)
Sensation of heaviness (2.5%)
Muscle spasms (2.5%)
Somnolence (37.5%)
Headache (10%)
Dizziness (5%)
Paraesthesia (2.5%)
Dysgeusia (5%)
Hypoaesthesia (2.5%)
Hypotonia (2.5%)
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
2.5 mg 2 times / day multiple, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Irritable Bowel Syndrome
Population Size: 10
Sources:
Other AEs: Headache...
Other AEs:
Headache (below serious, 3 patients)
Sources:
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Other AEs: Diabetes, Concussion...
Other AEs:
Diabetes (serious, 1 patient)
Concussion (serious, 1 patient)
Nausea (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 10%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hunger 10%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Chills 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Eye irritation 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hordeolum 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hypoaesthesia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hypotonia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Muscle spasms 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Palpitations 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Paraesthesia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Photophobia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Polydipsia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Sensation of heaviness 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Tachycardia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Upper respiratory tract infection 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Vision blurred 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Fatigue 30%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Somnolence 37.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dry mouth 40%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dizziness 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dysgeusia 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Feeling hot 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Feeling of relaxation 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Thirst 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Increased appetite 7.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Headache below serious, 3 patients
2.5 mg 2 times / day multiple, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Irritable Bowel Syndrome
Population Size: 10
Sources:
Nausea below serious, 5 patients
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Concussion serious, 1 patient
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Diabetes serious, 1 patient
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (pharmacogenomic study)
Comment: Published data indicate a 2- to 3-fold higher dronabinol exposure in individuals carrying genetic variants associated with diminished CYP2C9 function
Page: 13.0
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.
1999 Aug
Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland.
2000 Apr 2
Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.
2000 Mar
Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences.
2000 Mar 15
Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.
2000 May 12
Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes.
2001 Apr
Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine.
2001 Apr
Urine drug screens in overdose patients do not contribute to immediate clinical management.
2001 Feb
Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse.
2001 Feb
delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1.
2001 Feb
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
2001 Feb
[Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats].
2001 Jan
Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.
2001 Jan
Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats.
2001 Jan 19
SPME-GC analysis of THC in saliva samples collected with "EPITOPE" device.
2001 Jul 15
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
2001 Jul 7
Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets.
2001 Mar
Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit.
2001 Mar
Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol.
2001 Mar
Comparison of ELISAs for opiates, methamphetamine, cocaine metabolite, benzodiazepines, phencyclidine, and cannabinoids in whole blood and urine.
2001 Mar
Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones.
2001 Mar
Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.
2001 Mar
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.
2001 May 11
Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
2001 May 11
Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice.
2001 May-Jun
Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
2001 May-Jun
Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
2001 May-Jun
The determination of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair using negative ion gas chromatography-mass spectrometry and high-volume injection.
2001 Oct
Identification and quantitation of 11-nor-delta9-tetrahydrocannabivarin-9-carboxylic acid, a major metabolite of delta9-tetrahydrocannabivarin.
2001 Sep
Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze.
2001 Sep
R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism.
2001 Sep 7
Patents

Sample Use Guides

Appetite Stimulation: Initially, 2.5 mg capsules should be administered orally twice daily, before lunch and supper. For patients unable to tolerate this 5 mg/day dosage, the dosage can be reduced to 2.5 mg/day, administered as a single dose in the evening or at bedtime. Antiemetic: it is best administered at an initial dose of 5 mg/m2, given 1 to 3 hours prior to the administration of chemotherapy, then every 2 to 4 hours after chemotherapy is given, for a total of 4 to 6 doses/day. Should the 5 mg/m2 dose prove to be ineffective, and in the absence of significant side effects, the dose may be escalated by 2.5 mg/m2 increments to a maximum of 15 mg/m2 per dose.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:01:16 GMT 2023
Edited
by admin
on Fri Dec 15 15:01:16 GMT 2023
Record UNII
7J8897W37S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DRONABINOL
HSDB   INN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
.DELTA.1-THC
Common Name English
MARINOL
Brand Name English
QCD 84924
Code English
ABBOTT 40566
Code English
THC
Common Name English
SP 104
Code English
TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM
MI  
Common Name English
TETRAHYDROCANNABINOL
Common Name English
(6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6A,7,8,10A-TETRAHYDRO-6H-DIBENZO(B,D)PYRAN-1-OL
Common Name English
DELTA-9-TETRAHYDROCANNABINOL
Common Name English
DELTA-9-THC
Common Name English
(6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
Common Name English
ABBOTT-40566
Code English
DRONABINOL [ORANGE BOOK]
Common Name English
J882F
Code English
Dronabinol [WHO-DD]
Common Name English
.DELTA.9-THC
Common Name English
QCD-84924
Code English
AD313 component dronabinol
Common Name English
DRONABINOL [VANDF]
Common Name English
dronabinol [INN]
Common Name English
TETRAHYDROCANNABINOL, DELTA-9 TRANS
Common Name English
SP-104
Code English
.DELTA.-9-TETRAHYDROCANNABINOL
Common Name English
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR,10AR)-
Common Name English
SCI-110 component dronabinol
Code English
DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Common Name English
.DELTA.9-TETRAHYDROCANNABINOL
Common Name English
DRONABINOL [USAN]
Common Name English
(-)-.DELTA.1-3,4-TRANS-TETRAHYDROCANNABINOL
Common Name English
AD-313 component dronabinol
Common Name English
DRONABINOL [HSDB]
Common Name English
DRONABINOL [MART.]
Common Name English
DRONABINOL [USP MONOGRAPH]
Common Name English
NSC-134454
Code English
TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM [MI]
Common Name English
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR-TRANS)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000008010
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
FDA ORPHAN DRUG 668918
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
DEA NO. 7369
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
NCI_THESAURUS C267
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
LIVERTOX NBK548830
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
WHO-ATC A04AD10
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
FDA ORPHAN DRUG 498215
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
CFR 21 CFR 1308.35
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
FDA ORPHAN DRUG 652218
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
FDA ORPHAN DRUG 54890
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
EU-Orphan Drug EU/3/16/1621
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
WHO-ATC N02BG10
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
NDF-RT N0000175782
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
FDA ORPHAN DRUG 628818
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
WHO-VATC QA04AD10
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
FDA ORPHAN DRUG 620417
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
FDA ORPHAN DRUG 549616
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
FDA ORPHAN DRUG 734820
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL465
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
RXCUI
10402
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
4109
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
NSC
134454
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
IUPHAR
2424
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
INN
5547
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
EVMPD
SUB06407MIG
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
DRUG BANK
DB00470
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
USAN
T-59
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID6021327
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
MERCK INDEX
m10624
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
TETRAHYDROCANNABINOL
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
CHEBI
66964
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
LACTMED
Dronabinol
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
FDA UNII
7J8897W37S
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
DAILYMED
7J8897W37S
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
MESH
D013759
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
NCI_THESAURUS
C867
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
PUBCHEM
16078
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
CAS
1972-08-3
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
SMS_ID
100000090615
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
HSDB
6471
Created by admin on Fri Dec 15 15:01:16 GMT 2023 , Edited by admin on Fri Dec 15 15:01:16 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MINOR
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT
Delta-9-tetrahydrocannabinol class | Euphoriant | Analgesic | Anti-inflammatory | Antioxidant | Antiemetic
TARGET -> AGONIST
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
METABOLITE ACTIVE -> PARENT
Equpotent to DELTA.9-TETRAHYDROCANNABINOL on CB1 receptors
PRODRUG -> METABOLITE ACTIVE
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY